Validating a breast cancer score in Spanish women. The MCC-Spain study

Dierssen-Sotos, Trinidad; Gómez‐Acebo, Inés; Palazuelos, Camilo; Fernández-Navarro, Pablo; Altzibar, Jone M; González-Donquiles, Carmen; Ardanáz, Eva; Alonso-Molero, Jéssica; Vidal, Carmen; Bayo-Calero, Juan; Tardón, Adonina; Salas, Dolores; Marcos‐Gragera, Rafael; Rodríguez-Cundín, Paz; Castaño‐Vinyals, Gemma; Ederra, María; Vilorio-Marqués, Laura; Amiano, Pilar; Pérez‐Gómez, Beatriz; Aragonés, Núria; Kogevinas, Manolis; Pollán, Marina; Llorca, Javier

doi:10.1038/s41598-018-20832-0

Cited by 5 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous study 11 from our research group, we assessed associations of a PRS, ERS, and methylation risk scores (MRSs), with BC incidence in the ESTHER cohort with up to 14 years of follow‐up. While the PRS (based on 269 single‐nucleotide polymorphisms (SNPs) derived from a GWAS 48 ) and ERS (Dierssen–Sotos score 49 ) showed positive individual associations with BC incidence, the MRS (based on 423 CpGs, derived from genetically predicted cytosine‐phosphate‐guanine (CpG) methylation levels 50 ) was not significantly associated with BC incidence. Adjusted ORs per SD increase in the score were 1.48 (95% CI, 1.16–1.90), 1.40 (95% CI, 1.09–1.80), and 1.07 (95% CI, 0.84–1.36) for the PRS, ERS, and MRS, respectively.…”

Section: Discussionmentioning

confidence: 99%

Cancer‐specific risk prediction with a serum microRNA signature

Raut,

Bhardwaj,

Schöttker

et al. 2024

Cancer Science

View full text Add to dashboard Cite

We recently derived and validated a serum‐based microRNA risk score (miR‐score) that predicted colorectal cancer (CRC) occurrence with very high accuracy within 14 years of follow‐up in a population‐based cohort study from Germany (ESTHER cohort). Here, we aimed to evaluate associations of the CRC‐specific miR‐score with the risk of developing other common cancers, including female breast cancer (BC), lung cancer (LC), and prostate cancer (PC), in the ESTHER cohort. MicroRNAs (miRNAs) were profiled by quantitative real‐time PCR in serum samples collected at baseline from randomly selected incident cases of BC (n = 90), LC (n = 88), and PC (n = 93) and participants without diagnosis of CRC, LC, BC, or PC (controls, n = 181) until the end of the 17‐year follow‐up. Multivariate logistic regression models were used to evaluate the associations of the miR‐score with BC, LC, and PC incidence. The miR‐score showed strong inverse associations with BC and LC incidence [odds ratio per 1 standard deviation increase: 0.60 (95% confidence interval [CI] 0.43–0.82), p = 0.0017, and 0.64 (95% CI 0.48–0.84),p = 0.0015, respectively]. Associations with PC were not statistically significant but pointed in the positive direction. Our study highlights the potential of serum‐based miRNA biomarkers for cancer‐specific risk prediction. Further large cohort studies aiming to investigate, validate, and optimize the use of circulating miRNA signatures for cancer risk assessment are warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Cancer‐specific risk prediction with a serum microRNA signature

Raut,

Bhardwaj,

Schöttker

et al. 2024

Cancer Science

View full text Add to dashboard Cite

show abstract

“…The MCC-Spain has provided results on the effects of different risk factors. For instance, night shift work increased the risk of more aggressive prostate cancers,23 although this excess risk almost disappeared 20 years after last exposure24; long-term consumption of calcium channel blockers was associated with higher breast cancer risk in overweight women25; adherence to the Western dietary patterns increased breast cancer risk in both premenopausal and postmenopausal women26; first validation in a European population of a risk model for breast cancer developed in American women using both modifiable and non-modifiable risk factors as well as 92 genetic variants27; use of environmental and genetic factors to elaborate a model to stratify the risk of colorectal cancer28; and adherence to the World Cancer Research Fund/American Institute for Cancer Research nutrition-based guidelines was associated with lower risk of colorectal and breast cancers, but not of prostate cancer 29. A complete list of published results from MCC-Spain appears in online supplementary table 2 and supplementary reference list.…”

Section: Findings To Datementioning

confidence: 99%

Cohort profile: the MCC-Spain follow-up on colorectal, breast and prostate cancers: study design and initial results

et al. 2019

Self Cite

View full text Add to dashboard Cite

PurposeSince 2016, the multicase-control study in Spain (MCC-Spain) has focused towards the identification of factors associated with cancer prognosis. Inception cohorts of patients with colorectal, breast and prostate cancers were assembled using the incident cases originally recruited.Participants2140 new cases of colorectal cancer, 1732 of breast cancer and 1112 of prostate cancer were initially recruited in 12 Spanish provinces; all cancers were incident and pathologically confirmed. Follow-up was obtained for 2097 (98%), 1685 (97%) and 1055 (94.9%) patients, respectively.Findings to dateInformation gathered at recruitment included sociodemographic factors, medical history, lifestyle and environmental exposures. Biological samples were obtained, and 80% of patients were genotyped using a commercial exome array. The follow-up was performed by (1) reviewing medical records; (2) interviewing the patients by phone on quality of life; and (3) verifying vital status and cause of death in the Spanish National Death Index. Ninety-seven per cent of recruited patients were successfully followed up in 2017 or 2018; patient-years of follow-up were 30 914. Most colorectal cancers (52%) were at clinical stage II or lower at recruitment; 819 patients died in the follow-up and the 5-year survival was better for women (74.4%) than men (70.0%). 71% of breast cancers were diagnosed at stages I or II; 206 women with breast cancer died in the follow-up and the 5-year survival was 90.7%. 49% of prostate cancers were diagnosed at stage II and 32% at stage III; 119 patients with prostate cancer died in the follow-up and the 5-year survival was 93.7%.Future plansMCC-Spain has built three prospective cohorts on highly frequent cancers across Spain, allowing to investigate socioeconomic, clinical, lifestyle, environmental and genetic variables as putative prognosis factors determining survival of patients of the three cancers and the inter-relationship of these factors.

show abstract

“…Although inflammation, diet, physical inactivity, weight, waist circumference and high body mass index (BMI), play a role as risk factors for PCa[ 6 – 12 ], their link to its etiology remain uncertain and the only well-established risk factors for PCa are family history, ethnicity and age[ 13 – 17 ]. Some genetic variants have also been found to be associated with BC and PCa; for instance, variants in BRCA1 and BRCA2 are strongly associated with BC[ 18 , 19 ], and some genetic scores have been developed for both types of cancer[ 20 , 21 ].…”

Section: Introductionmentioning

confidence: 99%

Pigmentation phototype and prostate and breast cancer in a select Spanish population—A Mendelian randomization analysis in the MCC-Spain study

et al. 2018

Self Cite

View full text Add to dashboard Cite

IntroductionPhototype has been associated with an increased risk of prostate cancer, and it is yet unknown if it is related to other hormone-dependent cancers, such as breast cancer or whether this association could be considered causal.MethodsWe examined the association between the phototype and breast and prostate cancers using a Mendelian randomization analysis. We studied 1,738 incident cases of breast cancer and another 817 cases of prostate cancer. To perform a Mendelian randomization analysis on the phototype—cancer relationship, a genetic pigmentation score was required that met the following criteria: (1) the genetic pigmentation score was associated with phototype in controls; (2) the genetic pigmentation score was not associated with confounders in the relationship between phototype and cancer, and (3) the genetic pigmentation score was associated with cancer only through its association with phototype. Once this genetic score is available, the association between genetic pigmentation score and cancer can be identified as the association between phototype and cancer.ResultsThe association between the genetic pigmentation score and phototype in controls showed that a higher genetic pigmentation score was associated with fair skin, blond hair, blue eyes and the presence of freckles. Applying the Mendelian randomization analysis, we verified that there was no association between the genetic pigmentation score and cancers of the breast and prostate.ConclusionsPhototype is not associated with breast or prostate cancer.

show abstract

Validating a breast cancer score in Spanish women. The MCC-Spain study

Cited by 5 publications

References 29 publications

Cancer‐specific risk prediction with a serum microRNA signature

Cancer‐specific risk prediction with a serum microRNA signature

Cohort profile: the MCC-Spain follow-up on colorectal, breast and prostate cancers: study design and initial results

Pigmentation phototype and prostate and breast cancer in a select Spanish population—A Mendelian randomization analysis in the MCC-Spain study

Contact Info

Product

Resources

About